CN1930143B - 具有微粒体甘油三酸酯传递蛋白质抑制活性的被五元杂环取代的芳基哌啶或哌嗪 - Google Patents

具有微粒体甘油三酸酯传递蛋白质抑制活性的被五元杂环取代的芳基哌啶或哌嗪 Download PDF

Info

Publication number: CN1930143B
Authority: CN; China
Prior art keywords: alkyl; mol; mixture; formula; stirred
Prior art date: 2004-03-10
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Fee Related

Application number

CN2005800074663A

Other languages

English (en)

Chinese (zh)

Other versions

CN1930143A (zh

Inventor

L·米尔佩尔

L·J·J·巴克斯

L·亚洛斯科瓦

P·W·M·勒文斯

L·J·E·范德费肯

M·维勒沃耶

J·T·M·林德斯

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Janssen Pharmaceutica NV

Original Assignee

Janssen Pharmaceutica NV

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2004-03-10

Filing date

2005-03-07

Publication date

2012-04-04

2005-03-07 Application filed by Janssen Pharmaceutica NV filed Critical Janssen Pharmaceutica NV

2007-03-14 Publication of CN1930143A publication Critical patent/CN1930143A/zh

2012-04-04 Application granted granted Critical

2012-04-04 Publication of CN1930143B publication Critical patent/CN1930143B/zh

2025-03-07 Anticipated expiration legal-status Critical

Status Expired - Fee Related legal-status Critical Current

Links

0 C*N(*)C(N(*)C(C=I)=C)=* Chemical compound C*N(*)C(N(*)C(C=I)=C)=* 0.000 description 10

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Veterinary Medicine (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Chemical Kinetics & Catalysis (AREA)
Medicinal Chemistry (AREA)
Diabetes (AREA)
Obesity (AREA)
Hematology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Vascular Medicine (AREA)
Urology & Nephrology (AREA)
Child & Adolescent Psychology (AREA)
Emergency Medicine (AREA)
Endocrinology (AREA)
Physical Education & Sports Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

CN2005800074663A 2004-03-10 2005-03-07 具有微粒体甘油三酸酯传递蛋白质抑制活性的被五元杂环取代的芳基哌啶或哌嗪 Expired - Fee Related CN1930143B (zh)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
EP04075771		2004-03-10
EP04075771.8		2004-03-10
PCT/EP2005/051010 WO2005085226A1 (en)	2004-03-10	2005-03-07	Mtp inhibiting aryl piperidines or piperazines substituted with 5-membered heterocycles

Publications (2)

Publication Number	Publication Date
CN1930143A CN1930143A (zh)	2007-03-14
CN1930143B true CN1930143B (zh)	2012-04-04

Family

ID=34928108

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CN2005800074663A Expired - Fee Related CN1930143B (zh)	2004-03-10	2005-03-07	具有微粒体甘油三酸酯传递蛋白质抑制活性的被五元杂环取代的芳基哌啶或哌嗪

Country Status (26)

Country	Link
US (2)	US7504400B2 (de)
EP (1)	EP1751131B1 (de)
JP (1)	JP4846709B2 (de)
KR (1)	KR101171211B1 (de)
CN (1)	CN1930143B (de)
AR (1)	AR048316A1 (de)
AT (1)	ATE414698T1 (de)
AU (1)	AU2005219580B2 (de)
BR (1)	BRPI0508514A (de)
CA (1)	CA2558506C (de)
DK (1)	DK1751131T3 (de)
EA (1)	EA009455B1 (de)
ES (1)	ES2317206T3 (de)
IL (1)	IL177939A (de)
JO (1)	JO2537B1 (de)
MX (1)	MXPA06010253A (de)
MY (1)	MY142521A (de)
NZ (1)	NZ548817A (de)
PA (1)	PA8625401A1 (de)
PL (1)	PL1751131T3 (de)
PT (1)	PT1751131E (de)
SI (1)	SI1751131T1 (de)
TW (1)	TWI353984B (de)
UA (1)	UA85215C2 (de)
WO (1)	WO2005085226A1 (de)
ZA (1)	ZA200607542B (de)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2624102A1 (en)	2005-09-29	2007-04-12	Sanofi-Aventis	Phenyl- and pyridinyl- 1, 2 , 4 - oxadiazolone derivatives, processes for their preparation and their use as pharmaceuticals
EP1948629A1 (de) *	2005-10-31	2008-07-30	Janssen Pharmaceutica N.V.	Substituierte piperazine und piperidine als modulatoren des neuropeptid-y2-rezeptors
BRPI0715160A2 (pt)	2006-08-08	2013-06-11	Sanofi Aventis	imidazolidina-2,4-dionas substituÍdas por arilamimoaril-alquil-, processo para preparÁ-las, medicamentos compeendendo estes compostos, e seu uso
JP5498168B2 (ja) *	2006-12-01	2014-05-21	ブリストル−マイヤーズスクイブカンパニー	アテローム性動脈硬化および循環器疾患の治療のためのｃｅｔｐ阻害剤としてのｎ−（（３−ベンジル）−２，２−（ビス−フェニル）−プロパン−１−アミン誘導体
DE102007005045B4 (de)	2007-01-26	2008-12-18	Sanofi-Aventis	Phenothiazin Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
EP2025674A1 (de)	2007-08-15	2009-02-18	sanofi-aventis	Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
DE102007054497B3 (de)	2007-11-13	2009-07-23	Sanofi-Aventis Deutschland Gmbh	Neue kristalline Diphenylazetidinonhydrate und Verfahren zu deren Herstellung
WO2009079593A1 (en) *	2007-12-17	2009-06-25	Janssen Pharmaceutica N.V.	Piperazinyl derivatives useful as modulators of the neuropeptide y2 receptor
US20090197947A1 (en) *	2008-02-01	2009-08-06	The Research Foundation Of State University Of New York	Medicaments and methods for lowering plasma lipid levels and screening drugs
KR101273200B1 (ko)	2008-02-06	2013-06-17	펄마젠 쎄라퓨틱스 (시너지) 리미티드	화합물
WO2010003624A2 (en)	2008-07-09	2010-01-14	Sanofi-Aventis	Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof
WO2010068601A1 (en)	2008-12-08	2010-06-17	Sanofi-Aventis	A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
GB0913342D0 (en)	2009-07-31	2009-09-16	Astrazeneca Ab	Compounds - 801
DK2470552T3 (en)	2009-08-26	2014-02-17	Sanofi Sa	NOVEL, CRYSTALLINE, heteroaromatic FLUORGLYCOSIDHYDRATER, MEDICINES COVERING THESE COMPOUNDS AND THEIR USE
EP2571871B1 (de) *	2010-05-19	2017-06-21	Sandoz AG	Verfahren zur Herstellung von chiralen Triazolonen
US8933024B2 (en)	2010-06-18	2015-01-13	Sanofi	Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases
EP2766349B1 (de)	2011-03-08	2016-06-01	Sanofi	Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2012120056A1 (de)	2011-03-08	2012-09-13	Sanofi	Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
US8809325B2 (en)	2011-03-08	2014-08-19	Sanofi	Benzyl-oxathiazine derivatives substituted with adamantane and noradamantane, medicaments containing said compounds and use thereof
WO2012120058A1 (de)	2011-03-08	2012-09-13	Sanofi	Mit benzyl- oder heteromethylengruppen substituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120050A1 (de)	2011-03-08	2012-09-13	Sanofi	Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
US8710050B2 (en)	2011-03-08	2014-04-29	Sanofi	Di and tri- substituted oxathiazine derivatives, method for the production, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
WO2012120054A1 (de)	2011-03-08	2012-09-13	Sanofi	Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2683704B1 (de)	2011-03-08	2014-12-17	Sanofi	Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2683703B1 (de)	2011-03-08	2015-05-27	Sanofi	Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2567959B1 (de)	2011-09-12	2014-04-16	Sanofi	6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridin-4-carbonsäureamid-derivate als kinaseinhibitoren
WO2013175215A1 (en)	2012-05-22	2013-11-28	Autifony Therapeutics Limited	Triazoles as kv3 inhibitors
HRP20191860T1 (hr)	2013-03-13	2019-12-27	Forma Therapeutics, Inc.	Derivati 2-hidroksi-1-{4-[(4-fenilfenil)karbonil]piperazin-1-il}etan-1-ona i srodni spojevi kao inhibitori sintaze masnih kiselina (fasn) za liječenje raka
CN105143210A (zh) *	2013-04-25	2015-12-09	柳韩洋行	新的三唑酮衍生物或其盐以及含有其的药物组合物
EP3010889B1 (de)	2013-06-20	2018-10-03	Bayer CropScience Aktiengesellschaft	Arylsulfid- und arylsulfoxid-derivate als akarizide und insektizide
BR112015031291A2 (pt)	2013-06-20	2017-07-25	Bayer Cropscience Ag	derivados de sulfureto de arila e derivados de arilalquil sulfóxido como acaricidas e inseticidas
JP6522502B2 (ja)	2013-07-29	2019-05-29	協和発酵キリン株式会社	Ｗｎｔシグナル阻害剤
US10301318B2 (en) *	2014-06-25	2019-05-28	The General Hospital Corporation	Neuroactive compounds and methods of using the same
GB201601301D0 (en) *	2016-01-25	2016-03-09	Takeda Pharmaceutical	Novel compounds
ES2781309T3 (es) *	2016-05-27	2020-09-01	Bristol Myers Squibb Co	Triazolonas y tetrazolonas como inhibidores de ROCK
MX2019000512A (es)	2016-07-12	2019-05-02	Bayer Cropscience Ag	Compuestos biciclicos como plaguicidas.
CN110198942B (zh)	2017-01-24	2022-04-15	住友化学株式会社	稠合杂环化合物及含有其的组合物
AU2019318209B2 (en)	2018-08-10	2025-09-25	Diapin Therapeutics, Llc	Tri-peptides and treatment of metabolic, cardiovascular and inflammatory disorders
TWI767148B (zh)	2018-10-10	2022-06-11	美商弗瑪治療公司	抑制脂肪酸合成酶(fasn)
WO2020092395A1 (en)	2018-10-29	2020-05-07	Forma Therapeutics, Inc.	SOLID FORMS OF (4-(2-FLUORO-4-(1-METHYL-1 H-BENZO[d]IMIDAZOL-5-YL)BENZOYL) PIPERAZIN-1-YL)(1-HYDROXYCYCLOPROPYL)METHANONE
WO2022187206A1 (en) *	2021-03-01	2022-09-09	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Dual-target mu opioid and dopamine d3 receptors ligands; preparation and use thereof
WO2023225041A1 (en) *	2022-05-19	2023-11-23	Merck Sharp & Dohme Llc	Ripk1 inhibitors and methods of use
GB202216960D0 (en) *	2022-11-14	2022-12-28	Addex Pharmaceuticals Sa	Novel compounds

Citations (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN1449382A (zh) *	2000-09-04	2003-10-15	詹森药业有限公司	用作降脂质剂的多芳基羧酰胺类化合物

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB9826412D0 (en) *	1998-12-03	1999-01-27	Glaxo Group Ltd	Chemical compounds
GB0013383D0 (en) *	2000-06-01	2000-07-26	Glaxo Group Ltd	Therapeutic benzamide derivatives
GB0013346D0 (en) *	2000-06-01	2000-07-26	Glaxo Group Ltd	Therapeutic benzamide derivatives

2005
- 2005-03-07 JP JP2007502335A patent/JP4846709B2/ja not_active Expired - Fee Related
- 2005-03-07 MX MXPA06010253A patent/MXPA06010253A/es active IP Right Grant
- 2005-03-07 ES ES05716940T patent/ES2317206T3/es not_active Expired - Lifetime
- 2005-03-07 WO PCT/EP2005/051010 patent/WO2005085226A1/en not_active Ceased
- 2005-03-07 CN CN2005800074663A patent/CN1930143B/zh not_active Expired - Fee Related
- 2005-03-07 SI SI200530555T patent/SI1751131T1/sl unknown
- 2005-03-07 BR BRPI0508514-4A patent/BRPI0508514A/pt not_active Application Discontinuation
- 2005-03-07 PT PT05716940T patent/PT1751131E/pt unknown
- 2005-03-07 PL PL05716940T patent/PL1751131T3/pl unknown
- 2005-03-07 EP EP05716940A patent/EP1751131B1/de not_active Expired - Lifetime
- 2005-03-07 CA CA2558506A patent/CA2558506C/en not_active Expired - Fee Related
- 2005-03-07 EA EA200601660A patent/EA009455B1/ru not_active IP Right Cessation
- 2005-03-07 DK DK05716940T patent/DK1751131T3/da active
- 2005-03-07 NZ NZ548817A patent/NZ548817A/en not_active IP Right Cessation
- 2005-03-07 JO JO200526A patent/JO2537B1/en active
- 2005-03-07 AU AU2005219580A patent/AU2005219580B2/en not_active Ceased
- 2005-03-07 US US10/589,515 patent/US7504400B2/en not_active Expired - Lifetime
- 2005-03-07 KR KR1020067016095A patent/KR101171211B1/ko not_active Expired - Fee Related
- 2005-03-07 AT AT05716940T patent/ATE414698T1/de active
- 2005-03-08 PA PA20058625401A patent/PA8625401A1/es unknown
- 2005-03-09 MY MYPI20050983A patent/MY142521A/en unknown
- 2005-03-09 AR ARP050100904A patent/AR048316A1/es not_active Application Discontinuation
- 2005-03-09 TW TW094107062A patent/TWI353984B/zh not_active IP Right Cessation
- 2005-07-03 UA UAA200608684A patent/UA85215C2/uk unknown
2006
- 2006-09-07 IL IL177939A patent/IL177939A/en not_active IP Right Cessation
- 2006-09-08 ZA ZA200607542A patent/ZA200607542B/en unknown
2008
- 2008-12-22 US US12/341,567 patent/US7816360B2/en not_active Expired - Fee Related

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN1449382A (zh) *	2000-09-04	2003-10-15	詹森药业有限公司	用作降脂质剂的多芳基羧酰胺类化合物

Also Published As

Publication number	Publication date
BRPI0508514A (pt)	2007-08-14
US7504400B2 (en)	2009-03-17
US7816360B2 (en)	2010-10-19
PL1751131T3 (pl)	2009-04-30
AU2005219580B2 (en)	2010-07-08
US20100004263A1 (en)	2010-01-07
TW200540169A (en)	2005-12-16
TWI353984B (en)	2011-12-11
SI1751131T1 (sl)	2009-04-30
UA85215C2 (uk)	2009-01-12
JO2537B1 (en)	2010-09-05
KR101171211B1 (ko)	2012-08-07
PA8625401A1 (es)	2005-09-28
WO2005085226A1 (en)	2005-09-15
EA009455B1 (ru)	2007-12-28
CN1930143A (zh)	2007-03-14
MY142521A (en)	2010-12-15
JP2007527897A (ja)	2007-10-04
EA200601660A1 (ru)	2006-12-29
AR048316A1 (es)	2006-04-19
CA2558506A1 (en)	2005-09-15
MXPA06010253A (es)	2007-02-16
PT1751131E (pt)	2009-02-13
NZ548817A (en)	2009-04-30
CA2558506C (en)	2012-09-11
AU2005219580A1 (en)	2005-09-15
US20070191383A1 (en)	2007-08-16
KR20070014121A (ko)	2007-01-31
IL177939A0 (en)	2006-12-31
EP1751131B1 (de)	2008-11-19
ATE414698T1 (de)	2008-12-15
ZA200607542B (en)	2008-05-28
JP4846709B2 (ja)	2011-12-28
IL177939A (en)	2011-08-31
HK1103582A1 (en)	2007-12-21
ES2317206T3 (es)	2009-04-16
DK1751131T3 (da)	2009-03-16
EP1751131A1 (de)	2007-02-14

Legal Events

Date	Code	Title	Description
2007-03-14	C06	Publication
2007-03-14	PB01	Publication
2007-05-16	C10	Entry into substantive examination
2007-05-16	SE01	Entry into force of request for substantive examination
2007-12-21	REG	Reference to a national code	Ref country code: HK Ref legal event code: DE Ref document number: 1103582 Country of ref document: HK
2012-04-04	C14	Grant of patent or utility model
2012-04-04	GR01	Patent grant
2012-09-28	REG	Reference to a national code	Ref country code: HK Ref legal event code: GR Ref document number: 1103582 Country of ref document: HK
2019-03-01	CF01	Termination of patent right due to non-payment of annual fee
2019-03-01	CF01	Termination of patent right due to non-payment of annual fee	Granted publication date: 20120404 Termination date: 20180307

Publication	Publication Date	Title
KR101171211B1 (ko)	2012-08-07	Ｍｔｐ를 저해하는 5-원 헤테로사이클에 의해 치환된 아릴 피페리딘 또는 피페라진
WO1998004554A1 (en)	1998-02-05	Chemokine receptor antagonists
CA2427660C (en)	2010-01-19	Biphenylcarboxamides useful as lipid lowering agents
US6054458A (en)	2000-04-25	Heterocyclic compounds
KR101052204B1 (ko)	2011-07-29	아포리포프로테인 ｂ 분비 저해제로서의 ｎ-아릴 피페리딘치환된 바이페닐카복스아미드
AU2002219115A1 (en)	2002-08-08	Biphenylcarboxamides useful as lipid lowering agents
US8158783B2 (en)	2012-04-17	MTP inhibiting tetrahydro-naphthalene-1-carboxylic acid derivatives
HK1103582B (en)	2012-09-28	Mtp inhibiting aryl piperidines or piperazines substituted with 5-membered heterocycles
NO337711B1 (no)	2016-06-06	Mtp-hemmende aryl-piperidiner eller -piperaziner substituert med 5-leddede heterocykler
HK1137011B (en)	2013-10-11	Mtp inhibiting tetrahydro-naphthalene-1-carboxylic acid derivatives